

# SCHISTOSOMIASIS

## PROGRESS REPORT 2001–2011 AND STRATEGIC PLAN 2012–2020

PROGRESS REPORT 2001–2011 AND STRATEGIC PLAN 2012–2020

Schistosomiasis remains a major public health problem with almost 240 million people, and more than 90% of them living in sub-Saharan Africa, requiring preventive chemotherapy. Schistosomiasis in humans results from infection with parasitic blood flukes of the genus *Schistosoma*. Six species of schistosomes cause infection in humans. While the disease is now predominantly in Africa, it also occurs in the Americas, the Eastern Mediterranean region, the Southeast Asian region and the Western Pacific.

Infection is acquired when parasitic larvae penetrate the skin of people exposed to infested freshwater. Early infection may be characterized by dermatitis. Followed by a systemic acute phase caused by the migration of the juvenile worms through the circulatory system. In later phases, parasite eggs from adult worms cause penetrate the mucosa of the urogenital tract and the intestine. In such organs, acute inflammation progressively becomes chronic, and hyperaemia, abnormal growths such as polyps and internal haemorrhage are gradually replaced by fibrosis and thickening of the tissues. Bladder cancer is a late-stage consequence of *S. haematobium* infection, while embolization of eggs from the intestine to the liver through the portal system is typical of infection with the other *Schistosoma* spp., and is responsible for progressive liver fibrosis, portal hypertension and ascites.

Progress is being made in the control of schistosomiasis as in 2010; 34.8 million people were treated for schistosomiasis in 30 countries. Access to the drug of choice, praziquantel has been improved through a donation of up to 250 million tablets per year, until schistosomiasis is eliminated. It is thought that transmission has been interrupted in 19 countries, but this requires confirmation. In the World Health Assembly resolution WHA65.21, Member States called for intensified control interventions and initiation of elimination programmes where possible. The resolution also called for guidelines toward elimination as well as procedures for the verification of interruption of treatment.



# SCHISTOSOMIASIS

**PROGRESS REPORT 2001–2011  
AND STRATEGIC PLAN 2012–2020**



**World Health  
Organization**

WHO Library Cataloguing-in-Publication Data

Schistosomiasis: progress report 2001 - 2011, strategic plan 2012 - 2020.

1.Schistosomiasis - prevention and control. 2.Schistosomiasis - epidemiology. 3.Schistosomiasis - drug therapy. 4.Program evaluation. 5.Health programs and plans. I.World Health Organization.

ISBN 978 92 4 150317 4

(NLM classification: WC 810)

**© World Health Organization 2013**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France.

WHO/HTM/NTD/PCT/2013.2



# *Contents*

<b>1. INTRODUCTION</b>	<b>1</b>
1.1 Schistosomiasis	1
1.2 Evolution of the strategic approach to control schistosomiasis	2
1.3 Resolution WHA54.19 on schistosomiasis and soil-transmitted helminth infections	3
1.4 Recommendations on morbidity control	3
1.5 Countries, areas and population groups eligible for preventive chemotherapy	5
1.6 From control to elimination	6
1.7 Aim of this document	8
<b>2. PROGRESS REPORT 2001–2011</b>	<b>9</b>
2.1 Performance	10
2.2 Impact	12
2.3 Challenges	14
2.3.1 Political commitment	14
2.3.2 Coordination	14
2.3.3 Communication	14
2.3.4 Technical capacity	15
2.3.5 Monitoring and evaluation	16
2.3.6 Operational guidance	16
2.3.7 Complementary public-health interventions	16
<b>3. ENDEMIC COUNTRIES AND THEIR CLASSIFICATION</b>	<b>17</b>
3.1 Status of countries endemic for schistosomiasis	17
3.2 Progression towards elimination of schistosomiasis	18
3.3 Resolution WHA65.21 on the elimination of schistosomiasis	20
<b>4. STRATEGIC PLAN 2012–2020</b>	<b>21</b>
4.1 Background	21
4.2 Vision, goals and objectives	22
4.3 Control of morbidity	23

4.4	Elimination of schistosomiasis as a public-health problem	26
4.5	Interruption of transmission	26
4.6	Verification of elimination of schistosomiasis transmission	27
4.7	Post-elimination surveillance	27
4.8	Strategic approaches to address challenges to schistosomiasis control	28
4.8.1	Political commitment	28
4.8.2	Coordination	30
4.8.3	Communication	32
4.8.4	Technical capacity	33
4.8.5	Monitoring and evaluation	34
4.8.6	Operational guidance	36
4.8.7	Complementary public-health interventions	38
4.9	Milestones	39
<b>5.</b>	<b>REGIONAL HIGHLIGHTS</b>	<b>41</b>
5.1.	African Region	42
5.2	Region of the Americas	45
5.3	Eastern Mediterranean Region	47
5.4	European Region	49
5.5	South-East Asia Region	50
5.6	Western Pacific Region	51
<b>6.</b>	<b>PROJECTED NEEDS OF PRAZIQUANTEL</b>	<b>55</b>
6.1.	Population requiring preventive chemotherapy for schistosomiasis	55
6.2	Projected need of praziquantel, 2012–2020 and beyond	56
6.2.1	Scale-up and down	57
6.2.2	Population growth	57
6.2.3	Procurement data for 2011 and 2012	57
	<b>REFERENCES</b>	<b>59</b>
	<b>ANNEXES</b>	<b>67</b>
Annex I	Chronology of WHO official publication on schistosomiasis	67
Annex II	Issues of the <i>Weekly Epidemiological Record</i> on schistosomiasis	69
Annex III	Resolutions of the World Health Assembly on schistosomiasis	69
Annex IV	Revised estimates of people requiring preventive chemotherapy for schistosomiasis	70
Annex V	List of schistosomiasis- endemic countries according to WHO Technical Report Series No. 830	72



# Section 1

## Introduction

### 1.1 Schistosomiasis

Schistosomiasis is the disease resulting from infection with parasitic trematode worms of the genus *Schistosoma*. The main species of schistosomes infecting humans are listed here according to the chronological order in which they were first described: *S. haematobium* (1852), *S. japonicum* (1904), *S. mansoni* (1907), *S. intercalatum* (1934) and *S. mekongi* (1978) (1). *S. malayensis* (1988) has also been described and found in Malaysia but its public-health significance is still undetermined. *S. guineensis* was separated from *S. intercalatum* in 2003 (2). While the adult worms of all species reside within the blood vessels of the mammalian hosts, *S. haematobium* is responsible for urogenital schistosomiasis; the other species mainly affect the intestine and the liver.

Schistosomiasis is acquired when free-swimming parasitic larvae (cercariae) penetrate the skin of people exposed to infested freshwater. The clinical picture of schistosomiasis includes an early phase characterized by a dermatitis in the area where the cercariae penetrate the skin; a systemic acute phase caused by the migration of the juvenile worms (schistosomula) through the circulatory system; and finally, and most notably, an organ-specific chronic phase produced by the eggs laid by adult female *Schistosoma spp.* in the mucosa of the urogenital tract and the intestine. In such organs, acute inflammation progressively becomes chronic, and hyperaemia, abnormal growths such as polyps and internal haemorrhage are gradually replaced by fibrosis and thickening of the tissues. Bladder cancer is a late-stage consequence of *S. haematobium* infection, while embolization of eggs from the intestine to the liver through the portal system is typical of infection with the other *Schistosoma spp.*, and is responsible for progressive liver fibrosis, portal hypertension and ascites.

## 1.2 Evolution of the strategic approach to control schistosomiasis

The two pillars of schistosomiasis control have historically been represented by interventions targeting (i) the parasite within the human final host and (ii) the snail intermediate host, with the aim of decreasing morbidity and reducing transmission. The first attempts to control schistosomiasis employing such measures were made in the early 20th century in Egypt and Japan, respectively (3, 4). In 1920, Egypt implemented the first mass treatment intervention in adults and children alike using intravenous tartar emetic, a derivative of antimony, which had been successfully tested in the Sudan two years before (5). Following these examples, a number of national programmes started controlling schistosomiasis using treatment and/or snail control, often combined with provision of health education messages (6). Since its establishment in 1948, the World Health Organization (WHO) has recognized the public-health relevance of schistosomiasis and has developed a number of documents providing guidance and support to countries willing to embark on disease control interventions (*Annex 1; Annex 2*). Schistosomiasis control strategies have evolved as a function of the availability of new tools, and thus shifted from snail control to chemotherapy with the availability of safer medicines such as niridazole, metrifonate, oxamniquine and praziquantel (7). In addition, with the development of single-dose oral administration (e.g. of oxamniquine or praziquantel), the cost effectiveness and feasibility of large-scale preventive chemotherapy could be considered and assessed.

In the 1970s, research in Saint Lucia showed that chemotherapy was more cost effective in controlling schistosomiasis than snail control or provision of water supplies (8). Other research conducted in the 1970s–1980s suggested that most morbidity from schistosomiasis was due to heavy-intensity infections and that those with heavy infections should be targeted for treatment (9–11). Heavy infections could be detected in the field using urine filtration and the Kato-Katz techniques (12). In appreciating the high disease burden caused by schistosomiasis in sub-Saharan Africa and the lack of resources for adequate provision of water and sanitation in the endemic countries, a WHO Expert Committee recommended in 1985 that control programmes adopt morbidity control through chemotherapy as the main strategy for schistosomiasis control (13) while recognizing that access to potable water and adequate sanitation remains a challenge in many developing countries (14). With praziquantel as the drug of choice in the treatment of schistosomiasis and with the new strategy for morbidity control, pilot control programmes were undertaken in sub-Saharan Africa. Unfortunately, these proved unsustainable without external funding (15, 16). Some success was achieved with larger programmes that were able to scale up preventive chemotherapy for schistosomiasis control, as in China (17, 18) and Egypt (19, 20). In recent years, the significant reduction in the price of praziquantel, together with increasing advocacy and provision of resources for control of neglected tropical diseases (NTDs), has resulted in renewed launching of schistosomiasis control programmes in sub-Saharan Africa (21–24).

### **1.3 Resolution WHA54.19 on schistosomiasis and soil-transmitted helminth infections**

Even though WHO has recommended large-scale distribution of praziquantel to at-risk populations living in endemic areas since the 1970s and 1980s (7, 13, 25, 26), it was only in 2001 that the 54th World Health Assembly officially endorsed chemotherapy as the key public-health strategy to combat schistosomiasis (*Annex 3*) (27). Resolution WHA54.19 on schistosomiasis and soil-transmitted helminth infections urged Member States (i) to sustain successful control activities in low-transmission areas in order to eliminate schistosomiasis (and soil-transmitted helminth infections) as a public-health problem; (ii) to give high priority to implementing or intensifying control of schistosomiasis (and soil-transmitted helminth infections) in areas of high transmission; (iii) to monitor drug quality and efficacy of these control activities; and (iv) to ensure access to essential medicines against schistosomiasis (and soil-transmitted helminth infections) in all health services in endemic areas for the treatment of clinical cases and of groups at high risk of morbidity such as women and children. The goal of these activities would be to achieve a minimum target of regular administration of chemotherapy to at least 75%, and up to 100%, of all school-age children at risk of morbidity by 2010 (28).

Resolution WHA54.19 also recognized the importance of complementary public-health interventions, thus urging Member States to promote access to safe water, sanitation and health education through intersectoral collaboration as means of reducing transmission.

School-age children (aged 5–14 years) in endemic areas were the primary target of preventive chemotherapy interventions. This was justified by the fact that children are at highest risk of infection. Because of their recent exposure to infection and consequently the early stage of their chronic lesions, children would also benefit most from treatment interventions. Treatment during childhood therefore prevents chronic morbidity in later years (29).

Resolution WHA54.19 considered both schistosomiasis and soil-transmitted helminth infections. As school-age children are the main target population for both diseases, large-scale interventions using a combination of anthelmintics have

**预览已结束，完整报告链接和二维**

<https://www.yunbaogao.cn/report/index/report?report>